Fatal pregabalin poisoning in Japan: A case report.

Leg Med (Tokyo)

Department of Forensic Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.

Published: November 2024

AI Article Synopsis

  • * A fatal case in Japan revealed that a patient with multiple prescriptions, including pregabalin, overdosed; while initial screenings missed pregabalin, further tests confirmed its presence at a dangerous level.
  • * The case highlights the need for Japanese healthcare professionals to recognize the risks of pregabalin overdose and suggests that it should be included in routine drug screenings postmortem to better understand its potential dangers.

Article Abstract

Pregabalin is a new drug used for treating neuropathic pain, epilepsy, and anxiety disorders. Since 2010, the number of pregabalin prescriptions has dramatically increased in many countries. Although pregabalin has been considered to have a low potential for abuse and toxicity, fatal cases associated with pregabalin misuse or abuse have been increasing with an increased number of prescriptions. In addition, these fatalities are likely under-reported because pregabalin is commonly not part of postmortem routine drug screens. By contrast, pregabalin-related death has not yet been reported in Japan. We encountered a fatal case of pregabalin overdose. The patient has visited hospitals for benzodiazepine dependence, insomnia and anxiety disorder and has been prescribed pregabalin, flunitrazepam, and zolpidem. One day, his home caregivers, who were his constant companions to the hospitals, found him dead. Comprehensive drug screening performed in the police crime laboratory detected 7-aminoflunitrazepam and zolpidem, but not pregabalin in the cardiac blood. By contrast, we could find all drugs, including pregabalin, in our autopsy because pregabalin was a part of our routine drug screening. The pregabalin concentration was fatal at 18.5 μg/mL in the femoral blood, whereas 7-aminoflunitrazepam (0.1 μg/mL) and zolpidem (0.2 μg/mL) were lower than the fatal levels. We concluded that pregabalin played a primary role in the cause of death but not independently. This report addresses Japanese clinicians and forensic toxicologists to the risk of pregabalin poisoning, and pregabalin should be added in postmortem routine drug screening.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.legalmed.2024.102522DOI Listing

Publication Analysis

Top Keywords

pregabalin
14
routine drug
12
drug screening
12
pregabalin poisoning
8
postmortem routine
8
fatal
5
drug
5
fatal pregabalin
4
poisoning japan
4
japan case
4

Similar Publications

Anti-seizure medications (ASMs) are specific types of anticonvulsants used to treat epileptic seizures. However, several studies have shown an association between ASMs and an increased risk of hematological disorders, such as thrombocytopenia, aplastic anemia, and platelet function disorders leading to prolonged bleeding times. This review explores the existing literature on this topic, investigating a wide variety of ASMs, ranging from first-generation medications to newer ones.

View Article and Find Full Text PDF

Chronic kidney disease-associated pruritus (CKD-aP) is a frequent and distressing problem for individuals with chronic kidney disease (CKD) and end-stage renal disease. It affects around 20% of those with CKD and 40% of those with end-stage renal disease. Despite its clear association with poorer psychosocial and medical outcomes, it is often underreported by patients and frequently remains unnoticed by healthcare providers.

View Article and Find Full Text PDF

Background: Gabapentinoids, including gabapentin and pregabalin, are commonly used for neuropathic pain but have safety concerns. This study analyzed U.S.

View Article and Find Full Text PDF

Gabapentin and pregabalin are widely used in the management of neuropathic pain though their prescribing patterns, effectiveness, and safety profiles remain topics of ongoing research. This retrospective chart review analyzed the prevalence of gabapentinoid use in a chronic pain clinic over a one-year period from May 1, 2023, to April 30, 2024. The study examined patient records from four pain management physicians, focusing on those prescribed gabapentin or pregabalin.

View Article and Find Full Text PDF

Introduction Fibromyalgia is a chronic pain disorder characterized by widespread pain, fatigue, and sleep disturbances. The purpose of this study was to compare how well duloxetine, pregabalin, and milnacipran worked for fibromyalgia patients in terms of pain management, quality of life, and sleep quality. Methodology A prospective cohort research study with 193 fibromyalgia patients was carried out at the Abbas Institute of Medical Sciences, Muzaffarabad, Pakistan.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!